Our TRICARE South Region contract, which we were awarded in 2003, covers approximately 2.9 million beneficiaries.
The South Region is one of the three regions in the United States as defined by the Department of Defense.
The contract is for a five-year period subject to annual renewals at the federal government’s option with the second option period scheduled to begin April 1, 2005.
We currently have Medicaid contracts with the Puerto Rico Health Insurance Administration through June 30, 2005.
Our other Medicaid contracts are in Florida and Illinois, and are annual contracts.
As of December 31, 2004, Puerto Rico accounted for approximately 83% of our total Medicaid membership.
The loss of any of the contracts above or significant changes in these programs as a result of legislative action, including reductions in premium payments to us, or increases in member benefits without corresponding increases in premium payments to us, may have a material adverse effect on our financial position, results of operations, and cash flows.
Legal Proceedings We are party to a variety of legal actions in the ordinary course of business, including employment matters, breach of contract actions, tort claims, and shareholder suits involving alleged securities fraud.
A description of material legal actions in which we are currently involved is included under “Legal Proceedings” of Item 3 in Part 1.
We cannot predict the outcome of these suits with certainty, and we are incurring expenses in defense of these matters.
In addition, recent court decisions and legislative activity may increase our exposure for any of these types of claims.
Therefore, these legal actions could have a material adverse effect on our financial position, results of operations and cash flows.
Critical Accounting Policies and Estimates The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States of America.
The preparation of these financial statements and accompanying notes requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.
We continuously evaluate our estimates and those critical accounting policies related primarily to medical cost and revenue recognition as well as accounting for impairments related to our investment securities, goodwill, and long-lived assets.
These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results ultimately may differ from those estimates.
We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of our consolidated financial statements.
Medical Expense Recognition Medical expenses are recognized in the period in which services are provided and include an estimate of the cost of services which have been incurred but not yet reported, or IBNR.
IBNR represents a substantial portion of our medical and other expenses payable as follows:
## Table 0 ##
Estimating IBNR is complex and involves a significant amount of judgment.
Accordingly, it represents a critical accounting estimate.
Changes in this estimate can materially affect, either favorably or unfavorably, our results from operations and overall financial position.
For example, a 100 basis point, or 1 percent, change in the
Humana Inc.  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued) The total intrinsic value of stock options exercised during 2007 was $133.9 million, compared with $133.7 million during 2006 and $57.8 million during 2005.
Cash received from stock option exercises for the years ended December 31, 2007, 2006, and 2005 totaled $62.7 million, $49.2 million, and $36.4 million, respectively.
Total compensation expense related to nonvested options not yet recognized was $23.6 million at December 31, 2007.
We expect to recognize this compensation expense over a weighted average period of approximately 1.6 years.
Restricted Stock Awards Restricted stock awards are granted with a fair value equal to the market price of our common stock on the date of grant.
Compensation expense is recorded straight-line over the vesting period, generally three years from the date of grant.
The weighted average grant date fair value of our restricted stock awards was $63.59, $54.36, and $32.81 for the years ended December 31, 2007, 2006, and 2005, respectively.
Activity for our restricted stock awards was as follows for the year ended December 31, 2007:
## Table 1 ##
The fair value of shares vested during the years ended December 31, 2007, 2006, and 2005 was $3.4 million, $2.3 million, and $0.6 million, respectively.
Total compensation expense related to nonvested restricted stock awards not yet recognized was $44.7 million at December 31, 2007.
We expect to recognize this compensation expense over a weighted average period of approximately 1.4 years.
There are no other contractual terms covering restricted stock awards once vested.
The detail of benefits payable was as follows at December 31, 2012, 2011 and 2010:
## Table 2 ##
(1) IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date.
The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i. e.  a shorter time span results in a lower IBNR).
(2) Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.
(3) Military services benefits payable primarily represents the run-out of the claims liability associated with our previous TRICARE South Region contract that expired on March 31, 2012.
A corresponding receivable for reimbursement by the federal government is included in the military services receivable in the receivables table that follows.
(4) Other benefits payable include amounts owed to providers under capitated and risk sharing arrangements.
The increase in benefits payable in 2012 primarily was due to an increase in IBNR, primarily as a result of Medicare Advantage membership growth, partially offset by a $335 million decrease in the military services benefits payable due to the run-out of claims under the previous TRICARE South Region contract that expired on March 31, 2012, a decrease in amounts owed to providers under capitated and risk sharing arrangements, and a decrease in the amounts due to our pharmacy benefit administrator which fluctuate due to month-end cutoff.
Under the new TRICARE South Region contract effective April 1, 2012, the federal government retains the risk of the cost of health benefits and related benefit obligation as further described in Note 2 to the consolidated financial statements included in Item 8.
– Financial Statements and Supplementary Data.
The increase in benefits payable in 2011 primarily was due to an increase in processed but unpaid claims, including amounts due to our pharmacy benefit administrator, which fluctuate due to month-end cutoff, and an increase in military services benefits payable.
The increase in benefits payable in 2010 primarily was due to an increase in amounts owed to providers under capitated and risk sharing arrangements as well as an increase in IBNR, both primarily as a result of Medicare Advantage membership growth, partially offset by a decrease in the amount of processed but unpaid claims, including pharmacy claims, which fluctuate due to the month-end cutoff.
In addition to the timing of receipts for premiums and services fees and payments of benefits expense, other working capital items impacting operating cash flows primarily resulted from the timing of payments for the Medicare Part D risk corridor provisions of our contracts with CMS, changes in the timing of the collection of pharmacy rebates, and the timing of payments for premium rebates associated with minimum benefit ratios required under the Health Insurance Reform Legislation.

<table><tr><td></td><td> December 31, 2004 </td><td>Percentage of Total</td><td> December 31, 2003 </td><td> Percentage of Total </td></tr><tr><td></td><td colspan="4"> (dollars in thousands)</td></tr><tr><td>IBNR</td><td>$1,164,518</td><td>81.9%</td><td>$1,043,360</td><td>82.0%</td></tr><tr><td>Reported claims in process</td><td>97,801</td><td>6.9%</td><td>74,262</td><td>5.8%</td></tr><tr><td>Other medical expenses payable</td><td>159,691</td><td>11.2%</td><td>154,534</td><td>12.2%</td></tr><tr><td>Total medical and other expenses payable</td><td>$1,422,010</td><td>100.0%</td><td>$1,272,156</td><td>100.0%</td></tr></table>
<table><tr><td></td><td>Shares</td><td>Weighted Average Grant-Date Fair Value</td></tr><tr><td>Nonvested restricted stock at December 31, 2006</td><td>1,107,455</td><td>$45.86</td></tr><tr><td>Granted</td><td>852,353</td><td>63.59</td></tr><tr><td>Vested</td><td>-51,206</td><td>56.93</td></tr><tr><td>Forfeited</td><td>-63,624</td><td>49.65</td></tr><tr><td>Nonvested restricted stock at December 31, 2007</td><td>1,844,978</td><td>$53.61</td></tr></table>
<table><tr><td></td><td></td><td></td><td></td><td colspan="3">Change</td></tr><tr><td></td><td> 2012</td><td> 2011</td><td> 2010</td><td>2012</td><td>2011</td><td>2010</td></tr><tr><td></td><td colspan="6">(in millions)</td></tr><tr><td>IBNR -1</td><td>$2,552</td><td>$2,056</td><td>$2,051</td><td>$496</td><td>$5</td><td>$148</td></tr><tr><td>Reported claims in process -2</td><td>315</td><td>376</td><td>137</td><td>-61</td><td>239</td><td>-221</td></tr><tr><td>Military services benefits payable -3</td><td>4</td><td>339</td><td>255</td><td>-335</td><td>84</td><td>-24</td></tr><tr><td>Other benefits payable -4</td><td>908</td><td>983</td><td>1,026</td><td>-75</td><td>-43</td><td>344</td></tr><tr><td>Total benefits payable</td><td>$3,779</td><td>$3,754</td><td>$3,469</td><td>25</td><td>285</td><td>247</td></tr><tr><td>Payables from acquisition</td><td></td><td></td><td></td><td>-66</td><td>-29</td><td>0</td></tr><tr><td>Change in benefits payable per cash flow statement resulting in cash fromoperations</td><td></td><td></td><td></td><td>$-41</td><td>$256</td><td>$247</td></tr></table>

Question: what was the percent of the change in the weighted average grant date fair value of our restricted stock awards from 2006 to 2007